Get started
Work

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

Year: 2021
Type: article
Abstract: Multiple myeloma (MM) is the second most common hematologic disease worldwide 1 . CD38 is a type II transmembrane glycoprotein that is highly expressed on MM cells, and functions both as a receptor and as a multifunctional ectoenzyme 2 . CD38 monoclonal antibodies (mAbs) exhibit anti-MM activity via multiple mechanisms of action and are being evaluated in all stages of therapy. However, not all patients respond to CD38 mAb therapy; variability in response may be explained by both host-related and tumor-related factors 3 . The identification of biomarkers with predictive value for response could help to optimize and personalize the treatment of patients with relapsed/refractory multiple myeloma (RRMM). At present, CD38 receptor density (RD) on MM cells is the only biomarker with an association with clinical response to CD38 antibody therapies 4 .
DOI: 10.1038/s41408-021-00438-y
Authors: Paul G. Richardson, Thierry Facon, William I. Bensinger, Xavier Leleu, Frank Campana, Sandrine Macé, Marielle Chiron, Helgi van de Velde, Joseph Mikhael
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Centre Hospitalier Universitaire de Lille, Sanofi (France), Translational Genomics Research Institute, City of Hope
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,480
Funder: Sanofi
OpenAlex ID: W3135537396
FWCI: 0.812
Cites: 11
Cited by: 7
Related to: 10